[go: up one dir, main page]

GB201507541D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201507541D0
GB201507541D0 GBGB1507541.9A GB201507541A GB201507541D0 GB 201507541 D0 GB201507541 D0 GB 201507541D0 GB 201507541 A GB201507541 A GB 201507541A GB 201507541 D0 GB201507541 D0 GB 201507541D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1507541.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Priority to GBGB1507541.9A priority Critical patent/GB201507541D0/en
Publication of GB201507541D0 publication Critical patent/GB201507541D0/en
Priority to KR1020177005821A priority patent/KR102443258B1/en
Priority to ES15750051T priority patent/ES2725463T3/en
Priority to EP25194883.2A priority patent/EP4653463A2/en
Priority to NZ729270A priority patent/NZ729270B2/en
Priority to PE2017000203A priority patent/PE20170680A1/en
Priority to JP2017507739A priority patent/JP6654187B2/en
Priority to US15/329,402 priority patent/US11149090B2/en
Priority to EP19161728.1A priority patent/EP3552665A3/en
Priority to CN202111420044.6A priority patent/CN114099671A/en
Priority to AU2015303164A priority patent/AU2015303164B2/en
Priority to CN202411444693.3A priority patent/CN119280407A/en
Priority to MX2017001864A priority patent/MX382549B/en
Priority to SG11201701070WA priority patent/SG11201701070WA/en
Priority to CA2957146A priority patent/CA2957146A1/en
Priority to BR112017002729-1A priority patent/BR112017002729B1/en
Priority to EP15750051.3A priority patent/EP3180087B1/en
Priority to EA201790339A priority patent/EA201790339A1/en
Priority to CN201580043161.1A priority patent/CN106573981A/en
Priority to DK15750051.3T priority patent/DK3180087T3/en
Priority to MA047472A priority patent/MA47472A/en
Priority to CR20170096A priority patent/CR20170096A/en
Priority to PCT/EP2015/068598 priority patent/WO2016023960A1/en
Priority to UAA201701452A priority patent/UA119783C2/en
Priority to SV2017005380A priority patent/SV2017005380A/en
Priority to PH12017500229A priority patent/PH12017500229A1/en
Priority to IL250512A priority patent/IL250512B/en
Priority to NI201700015A priority patent/NI201700015A/en
Priority to CL2017000335A priority patent/CL2017000335A1/en
Priority to CONC2017/0001317A priority patent/CO2017001317A2/en
Priority to ECIEPI20178984A priority patent/ECSP17008984A/en
Priority to ZA2017/01126A priority patent/ZA201701126B/en
Priority to US17/475,592 priority patent/US20210403589A1/en
Priority to US18/538,429 priority patent/US20240228643A9/en
Ceased legal-status Critical Current

Links

GBGB1507541.9A 2014-08-12 2015-05-01 Antibodies Ceased GB201507541D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
UAA201701452A UA119783C2 (en) 2014-08-12 2015-08-12 COMBINED PREPARATION WITH ANTIBODY TO CD40
EP15750051.3A EP3180087B1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies
EA201790339A EA201790339A1 (en) 2014-08-12 2015-08-12 COMBINED DRUGS WITH ANTIBODIES TO CD40
EP25194883.2A EP4653463A2 (en) 2014-08-12 2015-08-12 Antibodies
NZ729270A NZ729270B2 (en) 2015-08-12 Combination therapies with anti cd40 antibodies
PE2017000203A PE20170680A1 (en) 2014-08-12 2015-08-12 JOINT TREATMENTS WITH ANTI CD40 ANTIBODIES
JP2017507739A JP6654187B2 (en) 2014-08-12 2015-08-12 Combination therapy using anti-CD40 antibody
US15/329,402 US11149090B2 (en) 2014-08-12 2015-08-12 Combination therapies with anti CD40 antibodies
EP19161728.1A EP3552665A3 (en) 2014-08-12 2015-08-12 Antibodies
CN202111420044.6A CN114099671A (en) 2014-08-12 2015-08-12 Combination therapy with anti-CD 40 antibodies
AU2015303164A AU2015303164B2 (en) 2014-08-12 2015-08-12 Combination therapies with anti CD40 antibodies
DK15750051.3T DK3180087T3 (en) 2014-08-12 2015-08-12 COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES
MX2017001864A MX382549B (en) 2014-08-12 2015-08-12 COMBINATION WITH ANTI-CD40 ANTIBODIES AND ANTI-PD-1 ANTIBODIES.
SG11201701070WA SG11201701070WA (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies
CA2957146A CA2957146A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies
BR112017002729-1A BR112017002729B1 (en) 2014-08-12 2015-08-12 COMBINATION THERAPY KIT FOR TREATING A SOLID TUMOR IN AN INDIVIDUAL, ANTIBODY OR ANTIGEN-BINDING PORTION THEREOF, USE AND PHARMACEUTICAL COMPOSITION
KR1020177005821A KR102443258B1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies
CN201580043161.1A CN106573981A (en) 2014-08-12 2015-08-12 Combination Therapies Utilizing Anti-CD40 Antibodies
ES15750051T ES2725463T3 (en) 2014-08-12 2015-08-12 Treatments combined with anti-CD40 antibodies
CN202411444693.3A CN119280407A (en) 2014-08-12 2015-08-12 Combination therapy using anti-CD40 antibodies
MA047472A MA47472A (en) 2014-08-12 2015-08-12 ANTIBODY
CR20170096A CR20170096A (en) 2014-08-12 2015-08-12 JOINT TREATMENTS WITH ANTI CD40 ANTIBODIES
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies
PH12017500229A PH12017500229A1 (en) 2014-08-12 2017-02-07 Combination therapies with anti cd40 antibodies
SV2017005380A SV2017005380A (en) 2014-08-12 2017-02-07 JOINT TREATMENTS WITH ANTI CD40 ANTIBODIES
IL250512A IL250512B (en) 2014-08-12 2017-02-08 Combination therapies with anti cd40 antibodies
NI201700015A NI201700015A (en) 2014-08-12 2017-02-09 JOINT TREATMENTS WITH ANTI CD40 ANTIBODIES
CL2017000335A CL2017000335A1 (en) 2014-08-12 2017-02-09 Joint treatments with anti cd40 antibodies
CONC2017/0001317A CO2017001317A2 (en) 2014-08-12 2017-02-10 Pharmaceutical composition with anti cd40 antibodies and kit
ECIEPI20178984A ECSP17008984A (en) 2014-08-12 2017-02-10 JOINT TREATMENTS WITH ANTI CD40 ANTIBODIES
ZA2017/01126A ZA201701126B (en) 2014-08-12 2017-02-15 Combination therapies with anti cd40 antibodies
US17/475,592 US20210403589A1 (en) 2014-08-12 2021-09-15 Combination therapies with anti cd40 antibodies
US18/538,429 US20240228643A9 (en) 2014-08-12 2023-12-13 Combination therapies with anti cd40 antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies

Publications (1)

Publication Number Publication Date
GB201507541D0 true GB201507541D0 (en) 2015-06-17

Family

ID=53489049

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1507541.9A Ceased GB201507541D0 (en) 2014-08-12 2015-05-01 Antibodies

Country Status (1)

Country Link
GB (1) GB201507541D0 (en)

Similar Documents

Publication Publication Date Title
IL259048A (en) Anti-ror1 antibodies
ZA201708128B (en) Tau-binding antibodies
SG10201913864RA (en) Anti-LAG-3 Antibodies
LT3354729T (en) Anti-garp antibody
ZA201705663B (en) Anti-transthyretin antibodies
ZA201800027B (en) Tau-binding antibodies
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
SG11201706126WA (en) Anti-transthyretin antibodies
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
ZA201705662B (en) Anti-transthyretin antibodies
IL268889A (en) Anti-epha4 antibody
GB201515351D0 (en) Antibody
GB201600871D0 (en) Antibody
LT3336185T (en) Antibody
IL257368A (en) Antibody
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
IL284022A (en) Anti-transthyretin antibodies
GB201518728D0 (en) Antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)